Biosimilars: SOP for Risk Assessment in Upstream Failures – V 2.0
To establish a structured approach for performing risk assessment in the event of upstream processing failures during biosimilar manufacturing, ensuring timely identification of root causes, impact analysis, and implementation of corrective and preventive actions (CAPA).
Click to read the full article.